Trial Profile
Is the optimal dose of preoperative statin associated with decreased end organ injury and better clinical outcome post cardiopulmonary bypass?
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2013
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; HMG-CoA reductase inhibitors
- Indications Coronary disorders; End-organ damage; Inflammation
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 21 Jan 2013 New trial record